Affordable Access

deepdyve-link
Publisher Website

Loss of von Willebrand factor high-molecular-weight multimers at acute phase is associated with detectable anti-ADAMTS13 IgG and neurological symptoms in acquired thrombotic thrombocytopenic purpura.

Authors
  • Béranger, Nicolas1
  • Benghezal, Sandrine1
  • Savigny, Sylvaine1
  • Capdenat, Sophie1
  • Joly, Bérangère S1
  • Coppo, Paul2
  • Stepanian, Alain1
  • Veyradier, Agnès3
  • 1 Service d'Hématologie Biologique, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Paris, France; EA3518, Institut Universitaire d'Hématologie Saint Louis, Université Paris Diderot, Paris, France. , (France)
  • 2 Service d'Hématologie, Centre National de référence des MicroAngiopathies Thrombotiques, Hôpital Saint-Antoine, Assistance Publique-Hôpitaux de Paris, Paris, France; Sorbonne Universités, Université Paris 6, Paris, France. , (France)
  • 3 Service d'Hématologie Biologique, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Paris, France; EA3518, Institut Universitaire d'Hématologie Saint Louis, Université Paris Diderot, Paris, France. Electronic address: [email protected] , (France)
Type
Published Article
Journal
Thrombosis research
Publication Date
Sep 01, 2019
Volume
181
Pages
29–35
Identifiers
DOI: 10.1016/j.thromres.2019.07.012
PMID: 31330376
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Thrombotic thrombocytopenic purpura (TTP) is a rare life threatening thrombotic microangiopathy caused by a severe functional deficiency of ADAMTS13, most frequently due to autoantibodies to ADAMTS13, thus termed acquired autoimmune TTP. ADAMTS13 specifically regulates the adhesive activity of von Willebrand factor (VWF) by cleaving its high-molecular-weight multimers (HMWM). We investigated whether VWF-HMWM level at acute phase of TTP could be a predictive factor for morbidity. We gathered clinical and biological data from a cohort of 114 patients with acquired TTP at acute phase. VWF-HMWM were assessed by electrophoretic analysis and by an ELISA measuring the capacity of VWF to bind to collagen (VWF:CB), and linear correlation between these two methods was carried out. We cross-referenced clinical and biological data with VWF-HMWM levels. VWF-HMWM levels were heterogeneous, but half of our patients were below normal range (50% if assessed by electrophoresis; 47.4% if assessed by ELISA). The correlation study between electrophoresis and ELISA reached statistical significance (r2 = 0.5979; p < 0.0001). Statistical analysis showed that loss of VWF-HMWM as assessed by VWF:CB < 70 IU/dL is associated with detectable anti-ADAMTS13 antibodies, severe neurological symptoms and thrombocytopenia (p < 0.05). Our results confirm that VWF-HMWM can be satisfactorily assessed by VWF:CB, much easier to perform than electrophoresis. The association highlighted between loss of VWF-HMWM, detectable anti-ADAMTS13 IgG and neurological symptoms may offer new insights to understanding the pathophysiology of acquired auto-immune TTP. Copyright © 2019 Elsevier Ltd. All rights reserved.

Report this publication

Statistics

Seen <100 times